摘要
Abstract
Objective To investigate the clinical efficacy,safety and efficacy of Anlotinib in the treatment of advanced non-small cell lung cancer(NSCLC)in the real world.Methods The clinical data of 77 patients with advanced NSCLC treated with Anrotinib from June 2018 to January 2021 in Qilu Hospital of Shandong University were analyzed to observe the efficacy of Anrotinib,factors affecting prognosis and adverse reactions.Results The objective response rate(ORR)and dis-ease control rate(DCR)were 9.1%(7/77)and 79.2%(61/77),respectively,and the median progression-free survival(mPFS)and median overall survival(mOS)were 4.9 months(95%CI=4.263-5.537)and 9.6 months(95%CI=9.133-10.067).The DCR of patients without lung metastasis,liver metastasis,brain metastasis and third-line treatment were higher than those of patients with lung metastasis,liver metastasis,brain metastasis and posterior treatment,and the differences were statistically significant(P＜0.05).Multivariate analysis using logistic regression model showed that three lines of treatment(β=1.496,OR=4.463,95%CI=1.051-18.948)was the independent influencing factor of DCR(P＜0.05).The results of univariate analysis showed that the mPFS was correlated with brain metastasis,adrenal metastasis,tumor stage and ECOG score,and the differences were statistically significant(P＜0.05).mOS was associated with liver metastasis,tumor stage and ECOG score,and the differences were statistically significant(P＜0.05).COX regression analysis showed that tumor stageⅢ(P=0.045,95%CI=0.178-0.981)and ECOG score 0-1(P=0.031,95%CI=0.350-0.950)were independent factors of mPFS,and ECOG score 0-1(P=0.045,95%CI=0.359-0.990)was an independent factor of mOS.The adverse reactions of allotinib were mainly grade 1 to 2.Conclusion Antirotinib is effective in third-line and above treatment of advanced NSCLC,and can improve the prognosis of patients with high safety.关键词
非小细胞肺癌/安罗替尼/疗效/安全性/预后因素Key words
Non-small cell lung cancer/Anlotinib/Effi-cacy/Safety/Prognostic factors分类
医药卫生
